Citations

Showing 10 of 108119 citations.

Quantitative analysis of nonvisit care activities performed by ambulatory care pharmacists in the outpatient primary care clinic setting
Tarpenning, Kimberly A. Kosloski , McGill, Sarah A., Yost, Kaitlin J. , Tumerman, Marc , Peterson, Jessica A.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 13, 2019 | Volume: 2 | Issue: 6 | Pages: 645-651

10.1002/jac5.1094 Get It

IntroductionThe value of pharmacists as direct patient care providers in integrated ambulatory care teams has been demonstrated. As the reimbursement landscape changes, patient care outside of office visits is increasing through nonvisit care.ObjectiveWe aimed to quantify the time spent by ambulatory care pharmacists on nonvisit care activities in the outpatient primary care clinic setting.MethodsData were collected from four outpatient ambulatory care practices in our institution over 12 weeks. The primary objective was to quantify the time spent performing nonvisit care activities. Secondary objectives were to quantify the number of patients affected, the number of nonvisit care activities, the types of medication therapy problems (MTPs) encountered during nonvisit care activities, and the resulting medication therapy interventions.ResultsA total of 1311 patients were affected during the study, and pharmacists spent a daily average of 1.6 hours performing nonvisit patient care. Among 1548 nonvisit care activities, staff face‐to‐face curbside consult was the most frequent (41%). Among 1866 MTPs identified (1.4 MTP per patient), the most common problems identified were need for education (31%), adverse medication events (21%), need for an additional medication (20%), and nonadherence (12%). The most common interventions were health care team education (28%), recommendation to switch medication (18%), patient education (17%), and start a new medication (14%).ConclusionAmbulatory care pharmacists spent considerable time performing nonvisit care, with multiple MTPs identified during these encounters. Health care teams frequently used pharmacists for nonvisit patient care. Further research is needed to determine the best utilization of pharmacist resources allocated to nonvisit care in an integrated ambulatory care practice.
Space Medicine in the Era of Civilian Spaceflight
Blue, Rebecca S. , Parazynski, Scott , Stepánek, Jan , Stepánek, Jan

Mayo Clinic

New England Journal of Medicine | March 13, 2019 | Volume: 380 | Issue: 11 | Pages: 1053-1060

10.1056/nejmra1609012 | PMID 30865799 Get It

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome
Innocenti, Federico , Qu, Xueping , Niedzwiecki, Donna , Tam, Rachel, Mahajan, Shilpi, Goldberg, Richard M. , Blanke, Charles D. , Sanoff, Hanna K. , Atkins, James N., Polite, Blasé N. , Lenz, Heinz‐Josef , Kabbarah, Omar , Zemla, Tyler J, Niedzwiecki, Donna , Ou, Fang‐Shu , Zemla, Tyler , Bertagnolli, Monica M. , Venook, Alan P. , Sanoff, Hanna

Mayo Clinic

Journal of Clinical Oncology | March 13, 2019 | Volume: 37 | Issue: 14 | Pages: 1217-1227

10.1200/jco.18.01798 | PMID 30865548 Get It

PURPOSE CALGB/SWOG 80405 was a randomized phase III trial that found no statistically significant difference in overall survival (OS) in patients with first-line metastatic colorectal cancer treated with chemotherapy plus either bevacizumab or cetuximab. Primary tumor DNA from 843 patients has been used to discover genetic markers of OS. PATIENTS AND METHODS Gene mutations were determined by polymerase chain reaction. Microsatellite status was determined by genotyping of microsatellites. Tumor mutational burden (TMB) was determined by next-generation sequencing. Cox proportional hazard models were used, with adjusting factors. Interaction of molecular alterations with either the bevacizumab or the cetuximab arms was tested. RESULTS Patients with high TMB in their tumors had longer OS than did patients with low TMB (hazard ratio [HR], 0.73 [95% CI, 0.57 to 0.95]; P = .02). In patients with microsatellite instability–high (MSI-H) tumors, longer OS was observed in the bevacizumab arm than in the cetuximab arm (HR, 0.13 [95% CI, 0.06 to 0.30]; interaction P < .001 for interaction between microsatellite status and the two arms). Patients with BRAF mutant tumors had shorter OS than did patients with wild-type (WT) tumors (HR, 2.01 [95% CI, 1.49 to 2.71]; P < .001). Patients with extended RAS mutant tumors had shorter OS than did patients with WT tumors (HR, 1.52 [95% CI, 1.26 to 1.84]; P < .001). Patients with triple-negative tumors (WT for NRAS/ KRAS/ BRAF) had a median OS of 35.9 months (95% CI, 33.0 to 38.8 months) versus 22.2 months (95% CI, 19.6 to 24.4 months ) in patients with at least one mutated gene in their tumors ( P < .001). CONCLUSION In patients with metastatic colorectal cancer treated in first line, low TMB, and BRAF and RAS mutations are negative prognostic factors. Patients with MSI-H tumors benefited more from bevacizumab than from cetuximab, and studies to confirm this effect of MSI-H are warranted.
Prevalence of sleep disorders in Parkinson’s disease patients in Ethiopia
Melka, Dereje , Tafesse, Abenet , Bower, James H., Assefa, Demeke

Mayo Clinic

No container title available | March 13, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.442/v1 Get It

Abstract ABSTRACT Background: Non motor symptoms (NMS) of Parkinson’s disease (PD) are common and can be more disabling than motor symptoms. Sleep disorders can be seen in up to 98% of patients with Parkinson disease. Poor sleep quality has been associated with poverty and race, and yet there has been no prior report on sleep disorders in those with PD living in sub Saharan Africa. We wished to document the prevalence of sleep disorders in PD patients in Ethiopia. Methods: We conducted a cross-sectional point prevalence study from July 1 to October 30, 2015 of all patients attending the neurology outpatient department in Tikur Anbessa and Zewuditu Memorial Hospitals, Addis Ababa, Ethiopia. Demographic data, clinical history and physical examination findings were collected from participants using a structured questionnaire. We used the Parkinson’s disease sleep scale version two (PDSS-2) and Epworth Sleepiness Scale (ESS) to assess the sleep symptoms. Results: Of the 155 patients surveyed, all patients reported some sleep problem. Over 23% of patients had a PDSS score > 30. Hoehn and Yahr score > 3 (OR 6.16; 95% CI 1.59-23.9, p=0.009) and PD symptom duration > 5 yrs (OR 5.11; 95% CI 1.41-18.5, p=.013) associated with a high PDSS-2 score. The median score of ESS was 9 (IQR = 5-12), with 77/155 (49.7%) of the patients having possible or definite excessive daytime somnolence. Conclusions: In Ethiopian PD patients, the prevalence of those with severe sleep disorders is the highest reported to date. The prevalence of possible/definite EDS is amongst the highest in the world. Further investigation into whether poverty or race explains this finding is needed. Keywords: Parkinson’s disease, Sleep disorders, Africa, poverty
Advancements in Cardiovascular Diagnostics
Fang, Karen L., Huang, Zhi , Lu, Yun , Yao, Yali, Li, Yan , Zhang, Bin

Mayo Clinic

Coronary and Cardiothoracic Critical Care | March 13, 2019 | Volume: No volume available | Issue: No issue available | Pages: 1-19

10.4018/978-1-5225-8185-7.ch001 Get It

The cardiology diagnostic are the methods of identifying current or past heart conditions, which can advise caregivers on patient diagnosis and provide a proper therapy plan, nowadays couple new diagnostic methods have been developed and some of them like radionuclide myocardial perfusion imaging, coronary computed tomography angiogram, cardiac magnetic resonance imaging, intravascular ultrasonography, optical coherence tomography, intravascular thermography, intravascular elastography, and near-infrared spectroscopy have been approved for clinical use. Not only the advanced technologies, the new biomarkers, and genetic markers may provide new potential targets for the diagnosis, therapy, and prevention of heart diseases.
Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases
Romagnoli, Micaela , Colby, Thomas V. , Berthet, Jean‐Philippe, Gamez, Anne Sophie, Mallet, Jean‐Pierre , Serre, Isabelle, Cancellieri, Alessandra , Solovei, Laurence , Dell’Amore, Andrea , Dolci, Giampiero , Guerrieri, Aldo, Reynaud, Paul, Bommart, Sébastien , Zompatori, Maurizio , Dalpiaz, Giorgia , Trisolini, Rocco , Suehs, Carey , Bourdin, Arnaud , Dell'Amore, Andrea , Dolci, Giampiero , Bommart, Sébastien , Trisolini, Rocco , Suehs, Carey M , Vachier, Isabelle , Molinari, Nicolas , Bourdin, Arnaud , Reynaud, Paul, Nava, Stefano , Vachier, Isabelle , Molinari, Nicolas

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 13, 2019 | Volume: 199 | Issue: 10 | Pages: 1249-1256

10.1164/rccm.201810-1947oc | PMID 30864813 Get It

Abstract Rationale The diagnostic concordance between transbronchial lung cryobiopsy (TBLC)—versus surgical lung biopsy (SLB) as the current gold standard—in interstitial lung disease (ILD) cases requiring histology remains controversial. Objectives To assess diagnostic concordance between TBLC and SLB sequentially performed in the same patients, the diagnostic yield of both techniques, and subsequent changes in multidisciplinary assessment (MDA) decisions. Methods A two-center prospective study included patients with ILD with a nondefinite usual interstitial pneumonia pattern (on high-resolution computed tomography scan) confirmed at a first MDA. Patients underwent TBLC immediately followed by video-assisted thoracoscopy for SLB at the same anatomical locations. After open reading of both sample types by local pathologists and final diagnosis at a second MDA (MDA2), anonymized TBLC and SLB slides were blindly assessed by an external expert pathologist (T.V.C.). Kappa-concordance coefficients and percentage agreement were computed for: TBLC versus SLB, MDA2 versus TBLC, MDA2 versus SLB, and blinded pathology versus routine pathology. Measurements and Main Results Twenty-one patients were included. The median TBLC biopsy size (longest axis) was 7 mm (interquartile range, 5–8 mm). SLB biopsy sizes averaged 46.1 ± 13.8 mm. Concordance coefficients and percentage agreement were: TBLC versus SLB: κ = 0.22 (95% confidence interval [CI], 0.01–0.44), percentage agreement = 38% (95% CI, 18–62%); MDA2 versus TBLC: κ = 0.31 (95% CI, 0.06–0.56), percentage agreement = 48% (95% CI, 26–70)%; MDA2 versus SLB: κ = 0.51 (95% CI, 0.27–0.75), percentage agreement = 62% (95% CI, 38–82%); two pneumothoraces (9.5%) were recorded during TBLC. TBLC would have led to a different treatment if SLB was not performed in 11 of 21 (52%) of cases. Conclusions Pathological results from TBLC and SLB were poorly concordant in the assessment of ILD. SLBs were more frequently concordant with the final diagnosis retained at MDA.
Cervical plexus and greater occipital nerve blocks: controversies and technique update
Greengrass, Roy A. , Bendtsen, Thomas Fichtner , Hadžić, Admir , Narouze, Samer

Mayo Clinic

Regional Anesthesia & Pain Medicine | March 13, 2019 | Volume: 44 | Issue: 6 | Pages: 623-626

10.1136/rapm-2018-100261 | PMID 30867277 Get It

Epstein‐Barr virus‐associated smooth muscle tumors after lung transplantation
Hirama, Takashi , Tikkanen, Jussi , Binnie, Matthew , Cleary, Sean, Pal, Prodipto , Cleary, Sean P.

Mayo Clinic

Transplant Infectious Disease | March 13, 2019 | Volume: 21 | Issue: 3 | Pages: No page available

10.1111/tid.13068 | PMID 30864272 Get It

AbstractBackgroundRecipients of solid organ transplants are prone to various complications that are seldom encountered in immunocompetent individuals. Post‐transplant lymphoproliferative disorder (PTLD) is the best known and commonest Epstein‐Barr Virus (EBV)‐associated malignancy post solid organ transplant. EBV‐associated smooth muscle tumors (EBV‐SMT) including leiomyomas and leiomyosarcomas are rare and much less studied than PTLD. We recently encountered two cases of EBV‐SMT post lung transplantation and here we summarize their clinical features and course together with a literature review.MethodClinical data and treatment details of two patients who developed EBV‐SMT were reviewed and retrieved up to December 31, 2017. English literature was searched through the PubMed database from 1965 to 2017 for studies of the association between lung transplant and EBV‐SMT.ResultsThe incidence of PTLD is higher among lung transplant recipients compared to kidney transplant recipients, an observation that has been attributed to stronger immune suppression in the lung patients. EBV‐SMT showed a higher incidence among kidney recipients than among lung recipients, suggesting that the degree of immunosuppression may be a less important factor in the development of EBV‐SMT. EBV‐SMT has most often been seen among lung transplant recipients with EBV mismatch.ConclusionsBecause EBV‐SMT is a rare tumor, its incidence, risk factors, and optimal management have not been well‐defined and further study is needed.
Expertise in Head and Neck Cutaneous Reconstructive Surgery
Deng, Min , Higgins, H. William , Lesiak, Kendra, Decker, Ashley B., Regula, Christie G., Stevenson, Mary L. , Raphael, Brian A., DePry, Jennifer L., Scott, Jeffrey F. , Bangash, H. , Ochoa, Shari A. , Ibrahimi, Omar A. , Shafai, Aria, Bordeaux, Jeremy S. , Carucci, John A. , Cook, Jonathan L. , Goldman, Glenn D., Rohrer, Thomas E. , Lawrence, Naomi, Deng, Min, Decker, Ashley

Mayo Clinic

Dermatologic Surgery | March 13, 2019 | Volume: 45 | Issue: 6 | Pages: 782-790

10.1097/dss.0000000000001844 | PMID 30829776 Get It

BACKGROUND The management of skin cancers has evolved with the development of Mohs micrographic surgery and a greater emphasis on surgical training within dermatology. It is unclear whether these changes have translated into innovations and contributions to the reconstructive literature. OBJECTIVE To assess contributions from each medical specialty to the cutaneous head and neck oncologic reconstructive literature. METHODS The authors conducted a systematic review of the head and neck reconstructive literature from 2000 through 2015 based on a priori search terms relating to suture technique, linear closure, advancement, rotation, transposition and interpolation flaps, and identified the specialty of the senior authors. RESULTS The authors identified 74,871 articles, of which 1,319 were relevant. Under suture technique articles, the senior authors were primarily dermatologists (58.2%) and plastic surgeons (20.3%). Under linear closure, the authors were dermatologists (48.1%), plastic surgeons (22.2%), and otolaryngologists (20.4%). Under advancement and rotation flaps, the senior authors were plastic surgeons (40.5%, 38.9%), dermatologists (38.1%, 34.2%), and otolaryngologists (14.4%, 21.6%). Under transposition and interpolation flaps, the senior authors were plastic surgeons (47.3%, 39.4%), dermatologists (32.3%, 27.0%), and otolaryngologists (15.3%, 23.4%). CONCLUSION The primary specialties contributing to the cutaneous head and neck reconstructive literature are plastic surgery, dermatology, and otolaryngology.
Acetazolamide Therapy in Patients with Heart Failure: A Meta-Analysis
Wongboonsin, Janewit , Cheungpasitporn, Wisit , Ungprasert, Patompong , Aeddula, Narothama Reddy , Mao, Michael A. , Aeddula, Narothama Reddy , Mao, Michael A , Cheungpasitporn, Wisit , Thongprayoon, Charat

Mayo Clinic

Journal of Clinical Medicine | March 13, 2019 | Volume: 8 | Issue: 3 | Pages: 349

10.3390/jcm8030349 | PMID 30871038 Get It

Background and objectives: Fluid overload and central sleep apnea are highly prevalent in patients with heart failure (HF). We performed this meta-analysis to assess the effects of acetazolamide therapy on acid/base balance and apnea indexes. Methods: A literature search was conducted using EMBASE, MEDLINE, and Cochrane Database from inception through 18 November 2017 to identify studies evaluating the use of acetazolamide in HF. Study results were analyzed using a random effects model. The protocol for this systematic review is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017065401). Results: Nine studies (three randomized controlled trials and six cohort studies) with a total of 229 HF patients were enrolled. After acetazolamide treatment, there were significant decreases in serum pH (mean difference (MD) of −0.04 (95% CI, −0.06 to −0.02)), pCO2 (MD of −2.06 mmHg (95% CI, −3.60 to −0.53 mmHg)), and serum bicarbonate levels (MD of −6.42 mmol/L (95% CI, −10.05 to −2.79 mmol/L)). When compared to a placebo, acetazolamide significantly increased natriuresis (standardized mean difference (SMD) of 0.67 (95% CI, 0.08 to 1.27)), and decreased the apnea-hypopnea index (AHI) (SMD of −1.06 (95% CI, −1.75 to −0.36)) and central apnea index (CAI) (SMD of −1.10 (95% CI, −1.80 to −0.40)). Egger’s regression asymmetry tests revealed no publication bias with p = 0.20, 0.75 and 0.59 for analysis of the changes in pH, pCO2, and serum bicarbonate levels with use of acetazolamide in HF patients. Conclusion: Our study demonstrates significant reduction in serum pH, increase in natriuresis, and improvements in apnea indexes with use of acetazolamide among HF patients.